Anti Scl-70 - Oslo universitetssykehus

January 29, 2018 | Author: Anonymous | Category: Science, Health Science, Immunology
Share Embed Donate


Short Description

Download Anti Scl-70 - Oslo universitetssykehus...

Description

Andre bindevevssykdommer

Abid Hussain Llohn [email protected] Immunologisk og transfusjonsmedisinsk avdeling Akershus universitetssykehus HF 06.10.2011

1

Andre bindevevssykdommer • • • •

Systemisk sklerose Polymyositt – dermatomyositt Sjögrens syndrom Blandet bindevevssykdom (MCTD)

2

Systemic Sclerosis • Systemic disease • History ¤ Hippocrates ¤ Carlo Curzio (1752) ¤ Fantonetti (1836) • Prevalence: 7/100.000 • 3-5 times higher risk for women • Peak onset at age 30-50 years

3

Systemic Sclerosis • Clinical

• Vascular system • Raynaud’s phenomenon 70% of patient initially present the symptoms 95% of all patients • Skin • • • • •

Diffuse pruritis, induration, tightness, pigmentary changes Microstomia Telangiectasias Calcinosis CREST(Calcinosis, Raynaud’s phenomenon, Esophagus 4 dysmotility, Sclerodactyli, Telangectasia)

Clinical (contd) • Gastroesophageal reflux, Barrett metaplasia, anal sphincter incompetence

• Interstitial fibrosis, pulmonary hypertension • Arthralgia, muscle weakness, acrosteolysis

• Facial pain and hand paresthesias due to sensory peripheral neuropathy

• Sicca syndrome in 5-7% of patients

• Renal crises • Erectile dysfunction, dyspareunia 5

Hypopigmentation. In black skin hypopigmentation and vitiligo can occur in scleroderma

1 The hands show an alteration in pigment and loss of shape on the terminal aspects of the fingers + flexion contractures of the fingers

Acrosclerosis and terminal digit resorption

2 Microstomia

6

3

4

6

6

5 Raynaud’s fenomen

Calcinosis

7

Telangiectasia.

6

Nail‐fold capillaroscopy: Tortuous, dilated capillary loops are seen at the base of the nail in 7 this patient.

8

7

Systemic Sclerosis • Classification

• Limited cutaneneous scleroderma (lcSSc) Raynaud’s phenomenon for years Skin changes limited to hands, face, feet, and forearms (acral distribution) Anti centromere antibodies (70%) CREST Pulmonary hypertension (10-15%)

• Diffuse cutaneous scleroderma (dcSSc)

• • • •

Raynaud’s phenomenon followed, within one year, by rapid skin changes (acral + truncal) Anti Scl-70 (30%), Anti-RNA polymerase III (12-15%) Renal crisis, interstitial fibrosis in lungs

Scleroderma sine scleroderma Environmentally induced scleroderma Overlap syndrome Pre-scleroderma 8

Major Immunologic features • Antinuclear antibodies (ANA) Sensitivity: 85% Specificity: 54%

• Anti centromere antibodies (ACA) Sensitivity: 24-33% Specificity:90- 99,9%

• Anti topoisomerase 1 (Scl-70) antibodies Sensitivity: 20-43% Specificity: 90-100% 9

Etiology/Pathogenesis • Complex & yet incompletely understood

• Immune activation, vascular damage, and excessive synthesis of extracellular matrix with deposition of increased amounts of structurally normal collagen are all known to be important in the development of scleroderma 10

Etiology/Pathogenesis • Genetic Factors • 20 times higher prevalence in Choctaw native-Americans in Oklahoma. HLA DQ7, DR2 strongly linked with anti-Scl-70. • HLA-DQA1 *0501 allel in 42% of Caucasian men with dsSSc, 29% in healthy men.

• Infectious Agents • CMV, Human Herpes virus 5 • Noninfectious Environmental • Petroleum-based products, Silica dust? Silicone implant? • Dugs: Bleomycin, Pentazocine, Cocaine • Microchimerism 11

Etiology/Pathogenesis • Role of autoantibodies • Association with highly specific autoantibodies • Presence at disease onset • Correlation between aAB titers & SSc activity & severity • SSc aAB share the feature of pathogenic immunoglobulins 12

Autoantibodies in SSc Autoantibody

Method of testing

Clinical association

Prognosis

ACA (24-33%)

IIF, IB, ELISA

lcSSc, CREST Better than anti-Scl-70 Pulmonary hypertension No benifit in following levels over time

Anti-Scl-70 (20-43%)

ID, CIE, IB, ELISA

dcSSC, pulmonary fibrosis, cor pulmonale

Worse prognoosis Levels fluctuate with severity of disease

Anti-RNAP (15%)

IP, EIA

dcSSc, cor pulmonale, renal disease

Increased mortality

AFA (4%)

IP

dcSSc, pulmonary hypertension, renal disease

Younger patients with internal organ involvement

Anti-RNP (8%)

IIF,ELISA,HA IP/CIE/ID

lcSSc, cor pulmonale, sicca, myositis

Benign prognosis, response to steroids

CIE; counterimmunoelectrophoresis, HA; hemagglutination, IB; immunoblotting, ID; immunoduffusion, IP; immunoprecipitation, IIF; indirect immunofluorescence, ELISA; enzyme-linked immunosorbent assay

13

Autoantibodies in SSc (cont) Autoantibody

Method of Clinical association testing

Prognosis

Anti-PM-Scl (3%) Anti-Th/TO (2-5%)

ID, IP

lcSSc PM/SSc overlap

Better response to steroids

IP

LCssC, ↓ joint involvment, ↑ Worse prognosis with puffy fingers, GIT reduced 10 years involvement, hypothyroidism survival

Anti-Ku

IB, IP, ELISA

Overlap syndrome with scleroderma features

Anti-Ro

ID, ELISA, IIF

Seen with 1/3-1/2 of SSc patients with sicca complex

Reveille JD: The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003, 5:80-93 14

Anti centromere antibody (ACA) • Initially described in 1980 • Six centromere proteins (CENP-A-F) • All sera containing ACA react

with

CENP-B (80 kDa). • Highly specific for SSc, strongly associated with CREST 15

Anti centromere antibody SSC versus: Normal controls Other CTDs Primary Raynaud

Non-SSc relatives

Sensitivity (%) 33 31 24 19

Specificity(%) 99.9 95-97 90 99

65 61 60 61

99.9 98 83 84

CREST versus: Normal controls

Other CTDs Primary Raynaud

SSc

Reveille JD: The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003, 5:80-93 Method: IIF

16

Anti-Scl-70 antibody • Scl-70 (70 kDa) was initially described in 1979 • Subsequent analysis (1986) revealed topoisomerase 1 Interconverts different topological forms of DNA Located in the nucleoplasm, nucleolus & nucleolar organizing region (NOR) • Variation in anti-Scl-70 levels (ELISA) with extent of disease involvement, even seronegative conversion with disease remission • IIF pattern is homogeneous or fine nuclear speckled, condensed chromatin material during mitosis 17

Anti-Scl-70 antibody SSC versus:

Sensitivity (%) 43

Specificity (%) 100

Other CTDs

43

90

Primary Raynaud

28

98

Non-SSc relatives

35.5

100

Normal controls

Reveille JD: The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003, 5:80-93 Method: ELISA 18

Treatment of SSc • Skin Thickening: D-pencillamine, methtrexate, interferon gamma, • • • • • • •

cyclophosphamide

Raynaud: Calcium blockers (Adalat), ACE inhibitors GIT symptoms: H2 blockers, proton pump inhibitors Pulmonary fibrosis: cyclophosphamide Renal crisis: ACE inhibitors Myositis: steroids Arthralgias: NSAIDs Autologous hematopoietic cell transplantation Blood. 2007 Aug 15;110(4):1388-96. 19

Polymyositis – dermatomyositis • • • •

Idiopathic inflammatory myopathy Incidence: 0,5-1/100.000/år 2 times higher risk for women Peak onset at age 50 (45-65) years 5-15 years in children

20

Polymyositis – Dermatomyositis Clinical •

1- Dermatologic features Heliotrope rash / Guttron Papules Poikiloderma, calcinosis, mechanic’s hand



2- Proximal muscle weakness Trunk, thighs, shoulders



3- Muscle

• • • • • •

pain on grasping or spontaneously 4- Non destructive arthritis or arthralgia 5- Increased serum CPK, Aldolase 6- EMG myogenic changes 7- Positive anti-Jo 1 antibody 8- Systemic inflammatory signs 9- Pathologic inflammatory signs



Diagnostic Criteria:

PM: ≥ 4 findings fra 2-9; DM: ≥ 4 findings fra 2-9 +Skin changes

21

Dermatomyositis. Poikilodermatous changes

Gottron’s papules.

Typical dermatomyositis shows the overlap features with early scleroderma, marked shininess and erythema on the knuckles.

22

22

Clinical -2 • • • • •

Cardiac: CHF, arrhythmia Lung: Interstitial lung disease, pneumonia Gastrointestinal: Dysphagia Joints: Arthralgias, symmetric arthritis Antisynthetase syndrome 23

Polymyositis – Dermatomyositis • • • • •

Type 1: Idiopathic Polymyositis (33%) Type 2: Idiopathic Dermatomyositis (25%) Type 3: Neoplasia related Type4: Childhood Polymyositis – Dermatomyositis Type 5: Polymyositis – Dermatomyositis associated with others rheumatic diseases • Type 6: Inclusion body myositis 24

Etiology/Pathogenesis • Genetic predisposition Association with DR3, DR5, DR7?

• Immunological abnormalities Perforin-dependent cytotoxicity of CD8 T cells in PM Expression of HLA class I in muscle cells Humoral immunity play larger role in DM Perivascular deposition of CD4 & C5b-C9 complex

• Infectious agents: Viruses: Coxsackievirus, echovirus, HTLV-1, HIV Toxoplasma and Borrelia species • Drugs: Hydroxyurea, Pencillamines, quinidine, phenylbutazone • Silicon breast implants?

25

Myositis Specific antibodies • Anti-tRNA-synthetase antibodies Anti-Jo-1 (anti-histidyl-) PL-7, PL-12, OJ, EJ

• Anti-SRP (Signal Recognition Particles) (classic PM) • Anti-Mi-2 (classic DM) 26

Anti-Jo-1 • • • • •

Antigen: histidyl-tRNA-synthetase, 50-52kD Present in 20-40% of PM patients Specificity >95% IgG1 isotype IIF pattern: Cytoplasmic speckled

• • • •

HLA-DR3/-DRw52 Interstitial lung disease Drug induced PM (D-pencillamine) Rare in children & DM 27

Anti-SRP • • • • •

Antigen: 7SL-RNA complex, 54-kD HLA DRw52 IIF pattern: cytoplasmic speckled Acute severe myositis No overlap with other CTDs

28

Myositis Specific antibodies Ab

Ag

Clinical association

IIF pattern

Jo-1

Histidyl-tRNA synthetase

PM 30%; DM 13% Spec> 95% Cytoplasm: speckled Lung fibrosis

PL-7

Threonyl-tRNA synthetase PM/DM 3%-5%, lung fibrosis

Cytoplasm: speckled

PL-12

Alanyl-tRNA-synthetase

PM/DM 3%, lung fibrosis

Cytoplasm: speckled

EJ

Glycyl-tRNA synthetase

PM 3%; DM 80%, Lung fibrosis

Cytoplasm: speckled

OJ

Isoleucyl-tRNA synthetase PM/DM 3%, lung fibrosis

SRP

54 kD protein in 7SLRNAcomplex

PM 5%; spec 83% Acute onset; severe

Cytoplasm: speckled Nucleolus

Mi-2

Nuclear protein complex

DM 15% - 35%; PM 5%-9%

Nucleoplasm Fine speckled

?

29

Myositis-overlap Antibodies Autoantibody

Clinical association

IIF pattern

PM-Scl

PM 8% -12% Scleroderma 25% PM/DM 5% - 10% Sjögren’s 90% PM/DM 4% - 17% SLE & SSc 30% MCTD 95% PM/DM 4% - 17% SLE & SSc 30%

Nucleolus & nucleus Homogen

SSA/Ro U1-nRNP

U2-nRNP

Nucleoplasm Fine speckled Nucleoplasm Speckled Nucleoplasm Speckled

30

Treatment • • • •

Corticosteroids Methotrexate, Cyclophosphamide IVIG Rituximab



Ref.



Dalakas MC, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.



Levine, TD. Rituximab in the treatment of Dermatomyositis. Arthritis Rheum 2005;52:601-607 31

Sjögren’s Syndrome • • • • • •

Systemic rheumatic disorder Mikulicz –1892 Sjögren – 1933 Prevalence. 1% (ca 40000 nordmenn) Female to male ratio: 9 to 1 Peak incidence: 40-50 years, Children: rare 32

Sjögren’s Syndrome Clinical

Sicca syndrome • Keratoconjunctivitis Dry eyes with, reduced tear production and sandy sensation under the lids; red eyes; photosensitivity

• Xerostomia • ↓ saliva production → difficulties in chewing, swallowing, even speech; abnormality in taste & smell; dental caries 33

Sjögren’s Syndrome • Primary Sjögren’s Syndrome Keratoconjunctivitis sicca

• Secondary Sjögren’s Syndrome Keratoconjunctivitis sicca

+ Other rheumatic disease 34

Organ manifestations in pSS • • • • •

Dry mucous membranes Joint pain Fibromyalgia (20%) Interstitial nephritis Chronic atrophic gastritis • Primary biliary cirrhosis • Peripheral neuropathy

• Mild interstitial disease • Myalgia, muscle

• • • •

weakness Autoimmune thyroiditis Pregnants + SSA/SSB risk for CHB Lymphomas ↑ risk CNS disorders 35

Other clinical features in pSS • • • • • • •

Fatigue 88% Dry skin 88% Arthralgia (hands) 85% Dryness in URT 83% Hoarseness 68% Dysphagia 68% Dry cough 54%

• • • • • • •

Diarrhea 54% Vaginitis 53% Dyspareunia 36% ↓sense of smell 37% Synovitis (hands) 32% Raynaud 29% Purpura (legs) 15% 36

Classification Criteria for SS American-European revised Rules for Classification of SS

• • • • • •

I- Ocular symptoms of inadequate tear production II- Oral symptoms of decreased saliva production III- Ocular signs of corneal damage due to inadequate tearing IV- Salivary gland histopathology demonstrating foci of lymphocytes V- Tests indicating impaired salivary gland function VI- Presence of autoantibodies (anti-Ro/SSA, anti-La/SSB, or both)



Primary SS: I- The presence of any 4 of 6, as long as either IV or VI is positive II- The presence of any 3 of the 4 objective items III-VI Secondary SS: The presence of item I or II plus 2 from III-IV plus another well defined CTD





Ref. Vitali, C, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:664-558. 37

Etiology/Pathogenesis • Genetics: HLA-DR3, HLA-B8, DQ-2 *

• Sex hormones

• Virus infection ** Epstein Barr virus Retrovirus: HIV, HTLV-I Coxsackievirus * Price EJ, et al. The etiopathogenesis of Sjogren's syndrome. Semin Arthritis Rheum 1995; 25:117-33. ** Venables PJ; et al. The response to Epstein-Barr virus infection in Sjogren's syndrome. J Autoimmun 1989;2:439-48. ** Triantafyllopoulou A, et al. Autoimmunity and coxsackievirus infection in primary Sjogren's syndrome. Ann N Y Acad Sci 2005;1050:389-96. ** Vernant, JC, et al. T-lymphocyte alveolitis, tropical spastic paresis, and Sjogren syndrome. Lancet 1988; 1:177.

38

Etiology/Pathogenesis

• Inflammatory reactivity • Cell mediated immune response • CD4 T cells (activated TH-1-type) predominates Cytokines (IL-1, IL-2, IL-6, TNF)

• B-cell abnormalities Hypergammaglobulinemia, elevated RF, antiRo/SSA & anti-La/SSB 39

Autoantibodies in SS • ANA 70-80%

• RF 80-90% • Anti-RO/SSA 70% • Anti-La/SSB 50% 40

Anti-La/SSB • 48 kD antigen: termination factor for RNA polymerase • IIF: Fine speckled

• Clinical: • • • • •

Sjögren’s syndrome (40-50%) SLE (15%) RA (5%) Systemic sclerosis (1%) MCTD (1600) • Mixed clinical features • SLE-like findings Polyarthritis, lymphadenopathy, pericarditis or pleuritis, leukopenia or thrombocytopenia, facial erythema

• Scleroderma –like findings Sclerodactyly, pulmonary fibrosis, hypomotility of esophagus

• Polymyositis-like findings Muscle weakness, ↑serum muscle enzymes, myogenic pattern on EMG

• Diagnosis: Positive anti-U1-RNP + one common symptom + one or more findings in two or three diseases Ref. Doria, A et al. J Rheumatol 1992;19:259

46

MCTD – Common clinical features Cumulatively At presentation Raynaud’s phenomenon Arthralgia/arthritis Esophageal hypomotility Pulmonary dysfunction Swollen hands Myositis Rash Leukopenia Sclerodactyly Pleuritis/pericarditis Pulmonary hypertension

96% 96% 66% 66% 66% 51% 53% 53% 49% 43% 23%

74% 68% 9% rare 45% 2% 13% 9% 11% 19% rare

47

Etiology/Pathogenesis • Immune response against apoptically modified self-antigens

• Molecular mimicry • B lymphocyte hyperactivity Ref. Greidinger EL, et al. A major B cell epitope present on the apoptotic but not the intact form of the

U1-

70-kDa ribonucleoprotein autoantigen. J Immunol 2004; 172: 709-16. Davies, JM. Introduction: Epitope mimicry as a component cause of autoimmune disease. Cell Mol Life Sci 2000; 57:523. 48

Autoantibodies in MCTD • ANA Sensitivity: > 95% with low specificity

• Anti-U1-RNP Sensitivity: > 90% IIF pattern: Coarse speckled

• Others: RF, Antiphosphlipid antibodies • Absence of anti-Sm, anti-dsDNA, anti-Scl-70, anticentrmere

49

Treatment/Prognosis • Steroids, NSAIDs, COX-2 inhibitors, Proton pump inhibitors, antimalarial agents, Prostaglandins, cytotoxic agents, Calcium channel blocking agents

• Occasionally evolve into SSc, SLE & other CTD

• Pulmonary hypertension is the most frequent disease-associated cause of death 50

View more...

Comments

Copyright � 2017 NANOPDF Inc.
SUPPORT NANOPDF